Edition:
India

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

34.36EUR
19 Jan 2018
Change (% chg)

-- (--)
Prev Close
€34.36
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
505,705
52-wk High
€37.10
52-wk Low
€10.26

Select another date:

Thu, Jan 18 2018

UPDATE 1-Largest Ablynx investor would consider improved Novo Nordisk bid

BRUSSELS, Jan 18 The largest shareholder in Belgian biotech group Ablynx regards the 2.6 billion euro ($3.2 billion) offer made by Denmark's Novo Nordisk as too low but would be willing to consider a higher figure.

Largest Ablynx shareholder says Novo Nordisk offer is too low

BRUSSELS, Jan 18 The largest shareholder in Belgian biotech group Ablynx said on Thursday that it believed a 2.6 billion euro ($3.2 billion) offer made by Denmark's Novo Nordisk was too low.

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

Ablynx soars after rejects Novo Nordisk's $3.1 billion biotech bid

COPENHAGEN/BRUSSELS Denmark's Novo Nordisk, the world's biggest insulin maker, went public with a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx on Monday, seeking a new source of growth by bolstering its treatments for rare blood disorders.

UPDATE 6-Ablynx soars after rejects Novo Nordisk's $3.1 bln biotech bid

* Bid underlines demand for biotech assets from large firms (Updates with exit of Ablynx chairman, closing share price)

LIVE MARKETS-Closing snapshot: Europe holds up as big falls hit UK stocks

* New year rally gathers pace as autos cement rally * STOXX 600 hits highest since August 2015 * Novo offers to buy Ablynx at 32 pct premium * Dialog Semi jumps after Q4 sales beat guidance * But weak results weigh on British stocks Jan 8 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Danilo Masoni. Reach him on Messenger to share your thoughts on market moves: danilo.maso

BRIEF-Ablynx Chairman, Peter Fellner, Resigns With Immediate Effect​

* DR PETER FELLNER DECIDED TO RESIGN FROM BOARD WITH IMMEDIATE EFFECT​

BRIEF-Ablynx's Board Says Takeover Proposal From Novo Nordisk Undervalues Company

* BOARD UNANIMOUSLY CONCLUDED THAT PROPOSAL FUNDAMENTALLY UNDERVALUES ABLYNX AND ITS STRONG PROSPECTS FOR CONTINUED GROWTH AND VALUE CREATION

Novo Nordisk bids $3.1 billion for Belgian biotech group Ablynx

BRUSSELS Denmark's Novo Nordisk , the world's biggest maker of insulin, has made a 2.6 billion euro ($3.1 billion) bid for Belgian biotech group Ablynx as it seeks to diversify and strengthen its business for treating rare blood disorders.

BRIEF-Novo Nordisk CFO Says Not Our Understanding That Any Other Bidder Is Pursuing Ablynx

Jan 8 NOVO NORDISK CHIEF FINANCIAL OFFICER JESPER BRANDGAARD SAID ON A CONFERENCE CALL IN RELATION TO BID FOR ABLYNX:

Select another date: